Acer Therapeutics reports Q1 EPS (79c), consensus (82c)
Cash and cash equivalents were $31.8M as of March 31, 2019, compared to $41.7M as of December 31, 2018. The company believes its cash position will be sufficient to fund its current operating and capital requirements into the first half of 2020. "Building on our success in 2018, we continued to execute in the first quarter of 2019 on our pre-commercial launch strategy for EDSIVO while growing and advancing our product pipeline," said Chris Schelling, CEO and Founder of Acer. "With a targeted FDA PDUFA action date of June 25, 2019, we have made significant progress in preparing for a potential launch of EDSIVO(TM), including the addition of seasoned commercial and medical affairs leaders with extensive sales, marketing, market access and product launch experience in orphan and ultra-orphan markets. Also, in April 2019, we announced the publication of the Paris registry data in JACC that supplements the previously-reported safety and efficacy of celiprolol in vEDS patients with a confirmed type III collagen mutation."